Tags

Type your tag names separated by a space and hit enter

[Antagonists of the type 3 serotonin receptor (5 -HT3) in IBS].
Nihon Rinsho 2006; 64(8):1487-90NR

Abstract

Irritable bowel syndrome (IBS) is a common chronic gastrointestinal (GI) disorder, but its pathophysiology remains unknown. 5-hydroxytryptamine (5-HT, serotonin) is an important neurotransmitter involved in the brain-gut connection. Alosetron, a 5-HT3 receptor antagonist, has been demonstrated in randomized, placebo-controlled trials (RCT) to be effective in diarrhea-predominant IBS(IBS-D). Constipation is the most common adverse event. Alosetron improved abdominal pain and discomfort and stool consistency in both female and male patients, but it did not improve other symptoms (sense of urgency, stool frequency and bloating) in male patients. Although less is known about the gender differences in therapeutic benefit, a new 5-HT3 antagonist, cilansetron, has demonstrated effectiveness in male and female IBS-D patients and is currently under clinical trials.

Authors+Show Affiliations

Second Department of Internal Medicine, National Defense Medical College.No affiliation info available

Pub Type(s)

English Abstract
Journal Article
Review

Language

jpn

PubMed ID

16898618

Citation

Komoto, Shunsuke, and Soichiro Miura. "[Antagonists of the Type 3 Serotonin Receptor (5 -HT3) in IBS]." Nihon Rinsho. Japanese Journal of Clinical Medicine, vol. 64, no. 8, 2006, pp. 1487-90.
Komoto S, Miura S. [Antagonists of the type 3 serotonin receptor (5 -HT3) in IBS]. Nippon Rinsho. 2006;64(8):1487-90.
Komoto, S., & Miura, S. (2006). [Antagonists of the type 3 serotonin receptor (5 -HT3) in IBS]. Nihon Rinsho. Japanese Journal of Clinical Medicine, 64(8), pp. 1487-90.
Komoto S, Miura S. [Antagonists of the Type 3 Serotonin Receptor (5 -HT3) in IBS]. Nippon Rinsho. 2006;64(8):1487-90. PubMed PMID: 16898618.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Antagonists of the type 3 serotonin receptor (5 -HT3) in IBS]. AU - Komoto,Shunsuke, AU - Miura,Soichiro, PY - 2006/8/11/pubmed PY - 2006/9/16/medline PY - 2006/8/11/entrez SP - 1487 EP - 90 JF - Nihon rinsho. Japanese journal of clinical medicine JO - Nippon Rinsho VL - 64 IS - 8 N2 - Irritable bowel syndrome (IBS) is a common chronic gastrointestinal (GI) disorder, but its pathophysiology remains unknown. 5-hydroxytryptamine (5-HT, serotonin) is an important neurotransmitter involved in the brain-gut connection. Alosetron, a 5-HT3 receptor antagonist, has been demonstrated in randomized, placebo-controlled trials (RCT) to be effective in diarrhea-predominant IBS(IBS-D). Constipation is the most common adverse event. Alosetron improved abdominal pain and discomfort and stool consistency in both female and male patients, but it did not improve other symptoms (sense of urgency, stool frequency and bloating) in male patients. Although less is known about the gender differences in therapeutic benefit, a new 5-HT3 antagonist, cilansetron, has demonstrated effectiveness in male and female IBS-D patients and is currently under clinical trials. SN - 0047-1852 UR - https://www.unboundmedicine.com/medline/citation/16898618/[Antagonists_of_the_type_3_serotonin_receptor__5__HT3__in_IBS]_ DB - PRIME DP - Unbound Medicine ER -